Developer docs
API playgroundTry for free, no card

Search company profiles

Asceneuron

Full company profile

uuid0000smc

Namestring
Asceneuron
Legal namestring
Asceneuron SA
Websiteurl
asceneuron.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Asceneuron SA is a clinical-stage biotechnology company founded in 2012 as a spin-off of Merck Serono's Alzheimer's drug discovery portfolio and headquartered at the EPFL Innovation Park in Eysins, Switzerland, with a US office in Cambridge, Massachusetts. The company is developing orally bioavailable, brain-penetrant small-molecule inhibitors of O-GlcNAcase (OGA), an enzyme that regulates protein O-GlcNAcylation, with the goal of preventing toxic tau and alpha-synuclein aggregation that drives neurodegenerative disease progression. Its pipeline comprises two clinical-stage OGA inhibitors — ASN51 (advancing to Phase 2 in Alzheimer's disease, with planned expansion to Parkinson's disease and ALS) and ASN90 (out-licensed to Ferrer for progressive supranuclear palsy, an orphan tauopathy) — plus a preclinical M1 Positive Allosteric Modulator program targeting cognitive dysfunction in Parkinson's disease dementia, Lewy Body dementia, and frontotemporal dementia. Both ASN51 and ASN90 have completed Phase 1 trials demonstrating safety, tolerability, high CNS target engagement (confirmed via PET imaging), and once-daily oral dosing.

The company's business model is asset-centric: rather than commercializing products directly, Asceneuron advances compounds through clinical proof-of-concept and then either licenses them to pharmaceutical partners for late-stage development and global commercialization (as with ASN90/Ferrer) or retains rights for self-development through Phase 2 before seeking a commercialization partner (the stated plan for ASN51). Revenue mechanics are therefore milestone-driven licensing and royalties (upfront fees, development/regulatory/commercial milestones, tiered double-digit royalties on net sales) supplemented by non-dilutive grant funding from disease foundations (Alzheimer's Drug Discovery Foundation, Michael J. Fox Foundation, Cure PSP). End customers are ultimately patients with Alzheimer's, Parkinson's, PSP, ALS, and related dementias, served indirectly through healthcare systems and pharmaceutical partners rather than through direct sales channels. The company is privately held, venture-backed (Series A CHF 30M led by Sofinnova Partners in 2015; Series C $100M led by Novo Holdings in July 2024), and operates with 11–50 employees.

Short descriptiontext

Asceneuron SA is a clinical-stage Swiss biotech developing orally bioavailable O-GlcNAcase (OGA) inhibitor small molecules — ASN51 for Alzheimer's disease and ASN90 (licensed to Ferrer) for progressive supranuclear palsy — to halt tau and alpha-synuclein aggregation in neurodegenerative diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLausanne, Switzerland
HQ citystring
Lausanne
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
OGA inhibitor therapeutics, neurodegenerative disease drugs, Alzheimer's disease treatments, tau pathology therapeutics, orphan tauopathy treatments
Industry1 code
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Neurodegenerative Disease Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Asceneuron generates revenue through licensing agreements where partners like Ferrer acquire worldwide rights to develop and commercialize drug candidates. Terms include upfront fees, development/regulatory/commercial milestone payments, and tiered double-digit royalties on net sales.

asceneuron.com
2Grant Funding
TypeProfessional Services
Description

Non-dilutive funding from foundations including The Michael J. Fox Foundation (Parkinson's research), Alzheimer's Drug Discovery Foundation (ASN51 Phase I), and Cure PSP for research and clinical development.

asceneuron.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Asceneuron discovers and develops orally administered small-molecule O-GlcNAcase (OGA) inhibitors as disease-modifying therapeutics for neurodegenerative disorders with high unmet medical needs, including Alzheimer's disease, Parkinson's disease, and orphan tauopathies such as Progressive Supranuclear Palsy (PSP). The company advances clinical-stage drug candidates internally and monetizes them through licensing partnerships with pharmaceutical companies and grants from research foundations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Completed 5 Phase 1 clinical trials for ASN51 demonstrating complete CNS uptake and high OGA enzyme occupancy
+2 more records
Product overview1 text field

Asceneuron is a clinical-stage biotech company developing a pipeline of orally administered small molecule O-GlcNAcase (OGA) inhibitors designed to halt abnormal protein aggregation in the brain. The company's proprietary clinical pipeline consists of two OGA inhibitors: ASN51 (potential best-in-class for Alzheimer's disease and Parkinson's disease, with expansion to ALS) and ASN90 (licensed to Ferrer for Progressive Supranuclear Palsy). Both compounds have completed Phase 1 studies demonstrating CNS uptake and OGA enzyme occupancy. The company also has a preclinical M1 PAM program for cognitive dysfunction in dementia. Asceneuron's approach targets both tau and alpha-synuclein pathologies to address neurodegenerative proteinopathies.

Product and service3 records
1ASN51
CategoryDrug Candidate (OGA Inhibitor)
Description

Asceneuron's next-generation O-GlcNAcase (OGA) inhibitor and lead clinical asset. An oral small molecule designed to inhibit the OGA enzyme and prevent tau and alpha-synuclein protein aggregation in the brain. ASN51 has completed five Phase 1 clinical trials demonstrating complete CNS uptake and high OGA enzyme occupancy confirmed by PET imaging, with a once-daily oral dosing profile. It is being advanced into Phase 2 development for Alzheimer's disease with planned expansion to Parkinson's disease and ALS.

2ASN90 (formerly ASN120290)
CategoryDrug Candidate (OGA Inhibitor, out-licensed)
Description

Clinical-stage O-GlcNAcase inhibitor in-licensed to Ferrer for the treatment of Progressive Supranuclear Palsy (PSP), an orphan tau-related neurodegenerative disease. ASN90 has received Orphan Drug Designation from both the US FDA and the European EMA, and has completed three Phase 1 clinical studies including safety/tolerability studies in healthy volunteers and a PET CNS target engagement study.

3M1 PAM (Positive Allosteric Modulator)
CategoryDrug Candidate (M1 PAM, preclinical)
Description

Preclinical-stage M1 muscarinic receptor positive allosteric modulator program targeting cognitive dysfunction in dementia indications including Parkinson's disease dementia (PDD), Lewy Body Dementia (LBD), and Frontotemporal dementia (FTD). The program is currently at 25% development stage.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-26
Description

Asceneuron joined the Critical Path for Alzheimer's Disease (CPAD) Consortium, collaborating with industry, academic, and regulatory experts to advance biomarkers for AD drug development, including tau PET imaging. The consortium has over 100,000 patient-level records and works with 370+ institutions worldwide.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-02-22
Description

Ferrer acquired exclusive worldwide rights to develop and commercialize ASN90 for progressive supranuclear palsy (PSP). Terms include upfront fee, multiple development/regulatory/commercial milestone payments, and tiered double-digit royalties on worldwide net sales. Ferrer will conduct Phase II clinical studies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Eisai
TypeBroad incumbent
Description

Co-developer with Biogen of Leqembi (lecanemab) for Alzheimer's with deep CNS franchise and tau-related research. Comparable as a leading Alzheimer's therapeutics developer and a potential strategic partner or acquirer for Asceneuron's ASN51.

TypeDirect peer
Description

Clinical-stage biotech developing therapeutics targeting tau, alpha-synuclein, and other proteinopathies for Alzheimer's, Parkinson's, and ATTR amyloidosis. Directly comparable to Asceneuron given dual tau/synuclein focus and similar clinical-stage profile.

TypeBroad incumbent
Description

Major neuroscience-focused pharma commercializing Leqembi (lecanemab) with Eisai for Alzheimer's and historically invested in tau programs. Comparable as both a competitor in neurodegenerative diseases and a potential acquirer of CNS-focused biotechs like Asceneuron.

TypeEmerging player
Description

Clinical-stage antisense oligonucleotide (ASO) leader with active programs targeting tau for Alzheimer's and other CNS indications. Comparable to Asceneuron as a clinical-stage neuroscience peer addressing tau pathology through a different (oligonucleotide) modality.

TypeEmerging player
Description

Clinical-stage biotech developing antisense oligonucleotide (ASO) therapies targeting tau and alpha-synuclein for Alzheimer's and Huntington's disease. Comparable as a clinical-stage neuroscience peer using different modality to target similar proteinopathies as Asceneuron's ASN51.

TypeEmerging player
Description

Clinical-stage biotech developing therapeutics for neurodegenerative diseases including Parkinson's and Alzheimer's, with a focus on lysosomal function and protein homeostasis. Comparable to Asceneuron given similar clinical-stage neuroscience profile and big-pharma partnerships.

TypeBroad incumbent
Description

Large pharma whose former Serono division originally developed the OGA inhibitor portfolio from which Asceneuron was spun out in 2012. Comparable as both a historical OGA program originator (MK-8719 program) and a potential strategic acquirer given CNS franchise interest.

TypeDirect peer
Description

Clinical-stage biotech developing tau-targeted immunotherapies and small molecules for neurodegenerative diseases. Highly comparable to Asceneuron given shared focus on tau pathology, clinical-stage pipeline, and similar target indications (Alzheimer's, Parkinson's).

TypeBroad incumbent
Description

Large pharma with the tau-targeting program semorinemab in Alzheimer's and broader neuroscience pipeline. Comparable as a major incumbent in neurodegenerative drug development competing for the same patient population and partnership opportunities as Asceneuron.

TypeBroad incumbent
Description

Large pharma with multiple Alzheimer's programs including Kisunla (donanemab) and historic tau-targeting programs. Comparable to Asceneuron as a key competitor in the Alzheimer's/tau space with vastly greater resources and commercialization capabilities.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Asceneuron

Neurodegenerative Disease Therapeuticsasceneuron.com

Asceneuron SA is a clinical-stage Swiss biotech developing orally bioavailable O-GlcNAcase (OGA) inhibitor small molecules — ASN51 for Alzheimer's disease and ASN90 (licensed to Ferrer) for progressive supranuclear palsy — to halt tau and alpha-synuclein aggregation in neurodegenerative diseases.

What Asceneuron does

Asceneuron SA is a clinical-stage biotechnology company founded in 2012 as a spin-off of Merck Serono's Alzheimer's drug discovery portfolio and headquartered at the EPFL Innovation Park in Eysins, Switzerland, with a US office in Cambridge, Massachusetts. The company is developing orally bioavailable, brain-penetrant small-molecule inhibitors of O-GlcNAcase (OGA), an enzyme that regulates protein O-GlcNAcylation, with the goal of preventing toxic tau and alpha-synuclein aggregation that drives neurodegenerative disease progression. Its pipeline comprises two clinical-stage OGA inhibitors — ASN51 (advancing to Phase 2 in Alzheimer's disease, with planned expansion to Parkinson's disease and ALS) and ASN90 (out-licensed to Ferrer for progressive supranuclear palsy, an orphan tauopathy) — plus a preclinical M1 Positive Allosteric Modulator program targeting cognitive dysfunction in Parkinson's disease dementia, Lewy Body dementia, and frontotemporal dementia. Both ASN51 and ASN90 have completed Phase 1 trials demonstrating safety, tolerability, high CNS target engagement (confirmed via PET imaging), and once-daily oral dosing.

The company's business model is asset-centric: rather than commercializing products directly, Asceneuron advances compounds through clinical proof-of-concept and then either licenses them to pharmaceutical partners for late-stage development and global commercialization (as with ASN90/Ferrer) or retains rights for self-development through Phase 2 before seeking a commercialization partner (the stated plan for ASN51). Revenue mechanics are therefore milestone-driven licensing and royalties (upfront fees, development/regulatory/commercial milestones, tiered double-digit royalties on net sales) supplemented by non-dilutive grant funding from disease foundations (Alzheimer's Drug Discovery Foundation, Michael J. Fox Foundation, Cure PSP). End customers are ultimately patients with Alzheimer's, Parkinson's, PSP, ALS, and related dementias, served indirectly through healthcare systems and pharmaceutical partners rather than through direct sales channels. The company is privately held, venture-backed (Series A CHF 30M led by Sofinnova Partners in 2015; Series C $100M led by Novo Holdings in July 2024), and operates with 11–50 employees.

Asceneuron firmographics

Firmographics
Name
Asceneuron
Legal name
Asceneuron SA
Website
https://asceneuron.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Short description
Asceneuron SA is a clinical-stage Swiss biotech developing orally bioavailable O-GlcNAcase (OGA) inhibitor small molecules — ASN51 for Alzheimer's disease and ASN90 (licensed to Ferrer) for progressive supranuclear palsy — to halt tau and alpha-synuclein aggregation in neurodegenerative diseases.
Ownership category
akta.pro rank

Asceneuron industry classification

Industry
Product category
Neurodegenerative Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • OGA inhibitor therapeutics
  • Neurodegenerative disease drugs
  • Alzheimer's disease treatments
  • Tau pathology therapeutics
  • Orphan tauopathy treatments

Where Asceneuron is headquartered

Location

Headquarters

HQ city
Lausanne
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

Asceneuron business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Licensing and Milestone Payments: Asceneuron generates revenue through licensing agreements where partners like Ferrer acquire worldwide rights to develop and commercialize drug candidates. Terms include upfront fees, development/regulatory/commercial milestone payments, and tiered double-digit royalties on net sales.
  2. Grant Funding: Non-dilutive funding from foundations including The Michael J. Fox Foundation (Parkinson's research), Alzheimer's Drug Discovery Foundation (ASN51 Phase I), and Cure PSP for research and clinical development.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Asceneuron product offering

Product offering

Core offering

Asceneuron discovers and develops orally administered small-molecule O-GlcNAcase (OGA) inhibitors as disease-modifying therapeutics for neurodegenerative disorders with high unmet medical needs, including Alzheimer's disease, Parkinson's disease, and orphan tauopathies such as Progressive Supranuclear Palsy (PSP). The company advances clinical-stage drug candidates internally and monetizes them through licensing partnerships with pharmaceutical companies and grants from research foundations.

Product overview

Asceneuron is a clinical-stage biotech company developing a pipeline of orally administered small molecule O-GlcNAcase (OGA) inhibitors designed to halt abnormal protein aggregation in the brain. The company's proprietary clinical pipeline consists of two OGA inhibitors: ASN51 (potential best-in-class for Alzheimer's disease and Parkinson's disease, with expansion to ALS) and ASN90 (licensed to Ferrer for Progressive Supranuclear Palsy). Both compounds have completed Phase 1 studies demonstrating CNS uptake and OGA enzyme occupancy. The company also has a preclinical M1 PAM program for cognitive dysfunction in dementia. Asceneuron's approach targets both tau and alpha-synuclein pathologies to address neurodegenerative proteinopathies.

Differentiator

Problem solved

Functional benefit

Products and services

  • ASN51 Asceneuron's next-generation O-GlcNAcase (OGA) inhibitor and lead clinical asset. An oral small molecule designed to inhibit the OGA enzyme and prevent tau and alpha-synuclein protein aggregation in the brain. ASN51 has completed five Phase 1 clinical trials demonstrating complete CNS uptake and high OGA enzyme occupancy confirmed by PET imaging, with a once-daily oral dosing profile. It is being advanced into Phase 2 development for Alzheimer's disease with planned expansion to Parkinson's disease and ALS.
  • ASN90 (formerly ASN120290) Clinical-stage O-GlcNAcase inhibitor in-licensed to Ferrer for the treatment of Progressive Supranuclear Palsy (PSP), an orphan tau-related neurodegenerative disease. ASN90 has received Orphan Drug Designation from both the US FDA and the European EMA, and has completed three Phase 1 clinical studies including safety/tolerability studies in healthy volunteers and a PET CNS target engagement study.
  • M1 PAM (Positive Allosteric Modulator) Preclinical-stage M1 muscarinic receptor positive allosteric modulator program targeting cognitive dysfunction in dementia indications including Parkinson's disease dementia (PDD), Lewy Body Dementia (LBD), and Frontotemporal dementia (FTD). The program is currently at 25% development stage.

Quantifiable outcome

  • Completed 5 Phase 1 clinical trials for ASN51 demonstrating complete CNS uptake and high OGA enzyme occupancy
  • +2 more outcomes

Companies that use Asceneuron

Customer profile

Segments4 records

Ideal customer profiles2 records

Asceneuron technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Asceneuron partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Critical Path Institute (CPAD Consortium)coreStrategic or Co-development Partner · 26 March 2024Asceneuron joined the Critical Path for Alzheimer's Disease (CPAD) Consortium, collaborating with industry, academic, and regulatory experts to advance biomarkers for AD drug development, including tau PET imaging. The consortium has over 100,000 patient-level records and works with 370+ institutions worldwide.
  • FerrercoreStrategic or Co-development Partner · 22 February 2023Ferrer acquired exclusive worldwide rights to develop and commercialize ASN90 for progressive supranuclear palsy (PSP). Terms include upfront fee, multiple development/regulatory/commercial milestone payments, and tiered double-digit royalties on worldwide net sales. Ferrer will conduct Phase II clinical studies.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Asceneuron competitors and assessment

Company assessment

Broad incumbents

  • Eisai: Co-developer with Biogen of Leqembi (lecanemab) for Alzheimer's with deep CNS franchise and tau-related research. Comparable as a leading Alzheimer's therapeutics developer and a potential strategic partner or acquirer for Asceneuron's ASN51.
  • Biogen: Major neuroscience-focused pharma commercializing Leqembi (lecanemab) with Eisai for Alzheimer's and historically invested in tau programs. Comparable as both a competitor in neurodegenerative diseases and a potential acquirer of CNS-focused biotechs like Asceneuron.
  • Merck & Co: Large pharma whose former Serono division originally developed the OGA inhibitor portfolio from which Asceneuron was spun out in 2012. Comparable as both a historical OGA program originator (MK-8719 program) and a potential strategic acquirer given CNS franchise interest.
  • Roche: Large pharma with the tau-targeting program semorinemab in Alzheimer's and broader neuroscience pipeline. Comparable as a major incumbent in neurodegenerative drug development competing for the same patient population and partnership opportunities as Asceneuron.
  • Eli Lilly: Large pharma with multiple Alzheimer's programs including Kisunla (donanemab) and historic tau-targeting programs. Comparable to Asceneuron as a key competitor in the Alzheimer's/tau space with vastly greater resources and commercialization capabilities.

Direct peers

  • Prothena: Clinical-stage biotech developing therapeutics targeting tau, alpha-synuclein, and other proteinopathies for Alzheimer's, Parkinson's, and ATTR amyloidosis. Directly comparable to Asceneuron given dual tau/synuclein focus and similar clinical-stage profile.
  • AC Immune: Clinical-stage biotech developing tau-targeted immunotherapies and small molecules for neurodegenerative diseases. Highly comparable to Asceneuron given shared focus on tau pathology, clinical-stage pipeline, and similar target indications (Alzheimer's, Parkinson's).

Emerging players

  • Ionis Pharmaceuticals: Clinical-stage antisense oligonucleotide (ASO) leader with active programs targeting tau for Alzheimer's and other CNS indications. Comparable to Asceneuron as a clinical-stage neuroscience peer addressing tau pathology through a different (oligonucleotide) modality.
  • Wave Life Sciences: Clinical-stage biotech developing antisense oligonucleotide (ASO) therapies targeting tau and alpha-synuclein for Alzheimer's and Huntington's disease. Comparable as a clinical-stage neuroscience peer using different modality to target similar proteinopathies as Asceneuron's ASN51.
  • Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegenerative diseases including Parkinson's and Alzheimer's, with a focus on lysosomal function and protein homeostasis. Comparable to Asceneuron given similar clinical-stage neuroscience profile and big-pharma partnerships.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Asceneuron social profiles

Digital presence

Asceneuron financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Asceneuron leadership team

Management profile

Number of profiles

Profiles9 records

Asceneuron funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Asceneuron M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Asceneuron

What does Asceneuron do?

Asceneuron discovers and develops orally administered small-molecule O-GlcNAcase (OGA) inhibitors as disease-modifying therapeutics for neurodegenerative disorders with high unmet medical needs, including Alzheimer's disease, Parkinson's disease, and orphan tauopathies such as Progressive Supranuclear Palsy (PSP). The company advances clinical-stage drug candidates internally and monetizes them through licensing partnerships with pharmaceutical companies and grants from research foundations.

Is Asceneuron a public or private company?

Asceneuron is a private company. It is classified as venture growth investor backed and is currently operating.

When was Asceneuron founded?

Asceneuron was founded in 2012. It employs 1 to 10 people.

Where is Asceneuron based?

Asceneuron is headquartered in Lausanne, Switzerland, in the Europe region.

How does Asceneuron make money?

Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are grant Funding.

Who are Asceneuron's main competitors?

Broad incumbents on record are Eisai, Biogen, Merck & Co, Roche and Eli Lilly. Direct peers are Prothena and AC Immune. Emerging players are Ionis Pharmaceuticals, Wave Life Sciences and Denali Therapeutics.

Does Asceneuron have an API?

No public API is recorded for Asceneuron.

What industry is Asceneuron in?

Asceneuron's product category is Neurodegenerative Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AETOSWireFerrer Acquires Worldwide Rights to ASN90, an O-GlcNAcase Inhibitor From Asceneuron, Exclusively to Treat Progressive Supranuclear Palsy (PSP)Ferrer acquired exclusive worldwide rights to ASN90, an O-GlcNAcase inhibitor, from Asceneuron for progressive supranuclear palsy. The deal includes an upfront fee, milestone payments, and tiered royalties, with Ferrer planning a phase II clinical study.PharmiWeb.comFerrer Completes Recruitment of 220 Patients for the PROSPER Study, a Phase II Clinical Trial in Progressive Supranuclear Palsy (PSP), Two Months Ahead of ScheduleSpanish pharmaceutical company Ferrer has completed patient recruitment for the PROSPER Phase II clinical trial evaluating FNP-223, an oral OGA enzyme inhibitor, in slowing progression of Progressive Supranuclear Palsy (PSP), having enrolled all 220 planned participants by October 6th, two months ahead of schedule. The randomized, double-blind, placebo-controlled trial is being conducted across 44 centers in the European Union, United Kingdom, and United States over a 14-month period. Ferrer in-licensed FNP-223 from Asceneuron for this rare, fatal neurodegenerative disease that currently has no approved disease-modifying therapies.PharmiWeb.comAsceneuron Secures $100 Million Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative DiseasesAsceneuron raised $100 million in Series C financing led by Novo Holdings, with new investors including EQT Life Sciences, OrbiMed, and SR One. The funds will advance its lead asset ASN51, an oral OGA inhibitor, into Phase 2 clinical development for Alzheimer's disease. The company plans to initiate its first Phase 2 study later this year.FinSMEsAsceneuron Raises $100M in Series C FinancingAsceneuron raised $100M in Series C funding led by Novo Holdings, with participation from EQT Life Sciences, OrbiMed, and SR One. The company will use the funds to advance its lead asset ASN51 into Phase 2 clinical development for Alzheimer's disease. It also plans to advance its pre-clinical pipeline in Parkinson's, ALS, and other neurodegenerative indications.MorningstarNovo Nordisk's Main Owner Leads $100 Million Financing of Biotech Firm AsceneuronNovo Holdings led a $100 million Series C round for Asceneuron, a biotech developing therapeutics for neurodegenerative diseases. The funds will advance its lead asset ASN51 into Phase 2 clinical development for Alzheimer's, with the first Phase 2 study planned later this year.ReutersNovo owner backs Swiss biotech Asceneuron in $100 million roundAsceneuron raised $100 million from investors including Novo Holdings, the investment arm of Novo Nordisk, to fund clinical development of its Alzheimer's drug ASN51. The Series C round will support a phase 2 trial starting later this year. Novo Holdings will hold a board seat on the Lausanne-based company.PR NewswireAsceneuron Secures $100 Million Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative DiseasesAsceneuron announced a $100 million oversubscribed Series C financing led by Novo Holdings, with new investments from EQT Life Sciences, OrbiMed, and SR One. The funds will advance its lead asset ASN51, an oral OGA inhibitor, into Phase 2 clinical development for Alzheimer's disease, with the first Phase 2 study planned later this year.PR NewswireEQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing roundEQT Life Sciences invested in Asceneuron's oversubscribed USD 100 million Series C, led by Novo Holdings. The funds will advance ASN51, an OGA inhibitor, into Phase 2 clinical development for Alzheimer's disease, with the first study planned later this year.PR NewswireNovo Holdings leads $100 million Series C financing of Asceneuron to advance groundbreaking therapy for Alzheimer's diseaseNovo Holdings led a $100 million Series C financing for Asceneuron, a biotech developing OGA inhibitors for neurodegenerative diseases. The funds will advance ASN51, an oral small molecule, into Phase 2 clinical development for Alzheimer's disease. Asceneuron plans to initiate its first Phase 2 study later this year.